Nature Biotechnology
- 24, 873 - 874 (2006)
Published online: 3 August 2006; | doi:10.1038/nbt0806-873
A reprise for collaborative financing in biotechJohn Ransom
Lone Tree, Colorado
Collaborative development financing could offer a more objective validation than a standard licensing deals because selection is based on the intrinsic value of the compounds, rather than strategic considerations that often sway a big pharma.
|
